Enzymit Ltd. Overview
Pro stress-test →Enzymit is building a cell-free production platform that aims to make bioproduction faster, simpler, cost-effective, and scalable. The company leverages complex computational design and deep learning algorithms to create novel enzymes for real-world applications. Its proprietary technology enables sustainable, localized biochemical manufacturing across pharmaceuticals, cosmetics, foodtech, and materials.
Strategic Profile
Pro stress-test →Enzymit is developing cell-free bio-production technology eliminating inefficiencies, complexity and cost of current bio-production technologies, with small, modular bio-reactors that can efficiently convert available feedstocks into valuable products. The AI-powered platform designs entirely new enzymes tailored for specific production challenges, enabling creation of molecules and materials previously unattainable or prohibitively costly to produce.
Competitive Landscape
Pro stress-test →Enzymit competes in synthetic biology and cell-free bioproduction against established biotech contract manufacturers (Lonza, Samsung BioLogics), emerging enzyme-design platforms (Genentech, DNA Script), and traditional fermentation-based biotech. Enzymit's competitive edge rests on AI-powered custom enzyme design enabling rapid optimization and cost reduction for niche, high-value syntheses.
Industry Context
Enzymit Ltd. operates in Industrial Biotechnology.
Key facts
Founded: 2020 · Headquarters: Ness Ziona, Israel · Employees: 11–50 · Revenue: Estimated early-stage; not disclosed · Market cap: N/A